Selinexor 20 mg (Selinex) tablets packaging front view

Rx Prescripttion Only-YMYL Medical Content

Selinex 20 mg Tablets

Selinexor 20mg tablets – Everest Pharmaceuticals Ltd.

Approved, in combination with dexamethasone, for adults with relapsed or refractory multiple myeloma (RRMM) after at least four prior therapies and refractory to two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 antibody (“penta-refractory” or “triple-class refractory” disease) — and, in combination with bortezomib and dexamethasone, for myeloma after one or more prior therapies. Also approved for certain diffuse large B-cell lymphoma (DLBCL) patients.

8.6 mo

Median overall survival in heavily pretreated, triple-class refractory myeloma (STORM trial)

26.2%

Objective response rate in patients with no other approved options (STORM)

First-in-class

Only approved oral XPO1 inhibitor — a genuinely novel mechanism

35% fewer

Clinic visits with weekly selinexor-bortezomib-dexamethasone vs standard twice-weekly regimen (BOSTON)

Confirm how many prior therapies and which drug classes have been tried

The penta-refractory indication requires at least 4 prior therapies and resistance to two proteasome inhibitors, two immunomodulatory drugs, and an anti-CD38 antibody. A different combination (with bortezomib) applies after just one prior therapy.

Baseline platelet count and overall blood count assessment

Thrombocytopenia is the most common and most dose-limiting side effect — baseline counts determine whether dose adjustment is needed before starting, and frequent monitoring is required especially in the first 2–3 months.

Establish a proactive nausea and hydration plan

Prophylactic anti-nausea medication and adequate fluid/caloric intake are recommended from the first dose, not added reactively — dehydration risk is significant, especially in older or frailer patients.

Discuss goals of care given the heavily pretreated contextDiscuss goals of care given the heavily pretreated context

For penta-refractory disease, this is typically among the few remaining treatment options — weigh the modest but meaningful survival benefit against significant fatigue, cytopenias, and the demands of close monitoring.

Important safety information: Selinexor can cause life-threatening thrombocytopenia (low platelets) with risk of serious bleeding, and life-threatening neutropenia with increased infection risk — platelet counts must be monitored at baseline and frequently during treatment, especially the first 3 months. Significant weight loss, decreased appetite, and dehydration are common and require active management. New onset or worsening cataracts have occurred. Hyponatremia (low sodium) is also frequently reported.

Medical Oncologist Review

Board-certified oncologist · 12+ years in thoracic malignancies

“Selinexor’s XPO1 mechanism gave us a genuinely new tool for patients who had run out of other options — penta-refractory myeloma is an extremely difficult population to treat. The side effects, especially thrombocytopenia and fatigue, are significant and need proactive management from day one, including anti-nausea medication before symptoms even start. For patients who’ve exhausted other lines, the BOSTON combination with bortezomib has also made it relevant much earlier in treatment, with a more manageable schedule.”

Content reviewed against FDA prescribing information, NCCN Guidelines v2.2024, and published Phase III trial data. Last updated June 2026.

Ready to discuss Tagrisso with your care team?

These steps help you have an informed conversation. A confirmed EGFR mutation result is the starting point for any treatment decision.

Medical disclaimer: This page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. It is a prescription medication that must only be used under the supervision of a qualified oncologist. Clinical outcomes data is drawn from published Phase III trials; individual results vary. Always consult your healthcare provider and refer to the full prescribing information before making any treatment decisions. Emergency: call your local emergency services or poison control immediately if you experience serious adverse effects.

Questions to ask my healthcare provider

What questions should I ask my hematologist about starting Selinex?

Here are key questions to bring to your hematologist about starting selinexor — given how heavily pretreated most patients are at this point, the conversation around realistic expectations and proactive side-effect management deserves as much weight as the practical dosing questions.

Before confirming Selinex(selinexor) as your treatment

Which combination am I being prescribed — selinexor with dexamethasone alone, or with bortezomib and dexamethasone — and which prior therapies qualify me for that specific regimen?
How many prior lines of treatment have I had, and which drug classes (proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies) have I already tried?
What other options exist at this point, including clinical trials or newer therapies like CAR-T or bispecific antibodies?
Realistically, what should I expect this treatment to accomplish given my treatment history?

About thrombocytopenia — the most dose-limiting side effect

What is my baseline platelet count, and does it affect my starting dose?
How often will my platelet count be checked, especially in the first 3 months?
What platelet level would trigger a dose reduction, treatment pause, or platelet transfusion?
What are the warning signs of serious bleeding — unusual bruising, bleeding gums, blood in urine or stool, severe headache — that need urgent attention?

About neutropenia and infection risk

How will my white blood cell counts be monitored?
What symptoms of infection — fever, chills, sore throat — should prompt an immediate call rather than waiting?

About nausea and nutrition — starting proactively, not reactively

Should I start anti-nausea medication before my first dose, and which one is recommended?
What does “adequate fluid and caloric intake” look like practically — should I be tracking my weight or fluid intake at home?
At what point would dehydration become a concern, and what are the warning signs?
Given how common weight loss is, should I be working with a dietitian alongside this treatment?

About hyponatremia

Will my sodium levels be checked regularly, and what symptoms of low sodium — confusion, severe fatigue, headache — should I watch for?

About cataracts

Should I have a baseline eye exam, and how often should that be repeated during treatment?
What vision changes would be significant enough to report right away?

About the dosing schedule

What is my exact dosing schedule — how many tablets, how many times per week, and on which specific days?
Does it matter if I take it with or without food?
What should I do if I vomit shortly after taking a dose — the guidance is generally not to repeat it, but I want to confirm this applies to my regimen.
What happens if I miss a dose entirely?

About managing fatigue

Fatigue is extremely common — are there strategies, activity pacing, or other approaches that help manage it during treatment?
Does fatigue tend to improve after the first cycle or two, or stay consistent throughout treatment?

About my specific situation

Given my age and overall health, am I at higher risk for more severe side effects or complications?
How does selinexor interact with my other current medications?
If I’m of childbearing potential, what precautions are needed during treatment?

About monitoring response

How will we track whether this is working — specific myeloma markers, imaging, or other tests?
How soon might we see an early response, and what would that look like?

About the longer road

If selinexor doesn’t work well enough or side effects become too difficult to manage, what would be considered next?
Are there clinical trials specifically relevant for heavily pretreated myeloma that I should know about now?
Are there patient assistance programs through Karyopharm if cost is a concern?

A practical tip: Because nausea and dehydration management work best when started before symptoms appear rather than after, it’s worth asking specifically whether anti-nausea medication will be prescribed alongside your first dose of selinexor — not held in reserve for if symptoms develop. Many patients find the first cycle is the most challenging, and proactive management from day one makes a meaningful difference in tolerating treatment long enough to see whether it’s working.

compare with other therapies

Compare selinexor vs CAR-T cell therapy for relapsed refractory multiple myeloma

What they fundamentally are

	Selinexor (Selinex)	CAR-T cell therapy
Type	Oral small-molecule drug	One-time cellular therapy — your own T-cells, genetically engineered
Administration	Take-home pills, weekly dosing, ongoing	Single infusion after a multi-step manufacturing process
Approved products	One drug (selinexor)	Idecabtagene vicleucel (Abecma/ide-cel) and ciltacabtagene autoleucel (Carvykti/cilta-cel) — both target BCMA on myeloma cells
Where it’s given	Outpatient, ongoing visits	Requires apheresis, cell manufacturing (weeks), then specialized infusion center admission

The efficacy gap is substantial

	Selinexor (STORM)	Ide-cel (KarMMa)	Cilta-cel (CARTITUDE-1)
Overall response rate	26%	73%	98%, with 83% achieving stringent complete response
Median PFS	3.7 months	8.8 months	2-year PFS of 60.5%
Median OS	8.6 months	24.8 months	2-year OS of 71% in patients achieving stringent CR

This is a meaningful difference, not a marginal one. A CAR-T cell therapy is, in some clinicians’ direct comparison, dramatically more effective than older salvage options that achieve response rates of around 30% at best in this same heavily pretreated population — selinexor falls into that lower-efficacy category, while CAR-T represents a genuine step-change in outcomes for this same patient group.

Why selinexor still exists despite CAR-T’s superior efficacy

This gap doesn’t mean selinexor is obsolete — it exists for important practical reasons:

Eligibility — CAR-T requires adequate organ function, reasonable performance status, and the ability to tolerate potentially serious acute toxicities. Older or frailer patients, or those with significant comorbidities, may not be candidates.

Timing — CAR-T manufacturing and the apheresis-to-infusion process takes weeks, during which a patient’s rapidly progressing myeloma may need “bridging therapy” to control disease — selinexor or other options can serve this purpose.

Access — CAR-T is only administered at specialized, certified treatment centers, often requiring travel and an extended stay near the treatment center. Selinexor can be managed by any oncology practice with standard monitoring capability.

Manufacturing failure or relapse after CAR-T — patients whose CAR-T product fails to be manufactured successfully, or who relapse after CAR-T, still need other options — selinexor remains relevant in this scenario too.

Cost and insurance authorization timing — CAR-T is extremely expensive and the approval/scheduling process can take time that a clinically declining patient may not have.

Side effect profiles — completely different categories of risk

	Selinexor	CAR-T cell therapy
Most distinctive risks	Thrombocytopenia, fatigue, nausea, hyponatremia	Cytokine release syndrome (CRS) and neurologic complications including immune effector-cell-associated neurotoxicity syndrome (ICANS)
Severity pattern	Chronic, manageable, ongoing	Acute, occurs in first 1-2 weeks after infusion, can be severe
Hospitalization	Generally outpatient	Required — specialized inpatient monitoring for CRS/ICANS
Long-term blood count effects	Present throughout treatment	Prolonged and recurrent cytopenias after the acute phase
Reversibility of decision	Can stop and switch relatively easily	One-time intervention — cannot be “undone” once cells are infused

CRS and ICANS are serious enough that these toxicities require specific management by skilled health professionals — meaning CAR-T isn’t just more effective, it’s also a fundamentally higher-acuity, higher-monitoring-burden treatment in its first few weeks, even though it’s a single infusion rather than ongoing therapy.

Where this fits in the treatment sequence today

Randomized trials have confirmed CAR-T’s superiority over standard regimens even earlier in the relapsed setting — KarMMa-3 showed ide-cel significantly improved PFS compared with standard regimens, and CARTITUDE-4 demonstrated improved PFS with cilta-cel versus standard-of-care therapy in lenalidomide-refractory myeloma, meaning CAR-T is increasingly being considered earlier in the disease course rather than reserved only for the most heavily pretreated, penta-refractory patients where selinexor was originally positioned.

Bottom line

If you’re eligible for CAR-T therapy and a center can perform it within your clinical timeline, the efficacy data strongly favors it over selinexor for relapsed/refractory myeloma — the response rate and survival differences are substantial, not marginal. Selinexor remains clinically important specifically for patients who aren’t CAR-T candidates, need bridging therapy while CAR-T is being arranged, have relapsed after CAR-T, or face access barriers (geographic, insurance, or capacity-related) that make CAR-T impractical in their timeframe. This is a conversation where asking directly “am I a candidate for CAR-T, and if so, how quickly could that be arranged” is one of the most important questions you can bring to your hematologist — ideally one affiliated with or able to refer to a CAR-T-certified center, since this decision can meaningfully change the treatment trajectory.

How does testing work

What does the XPO1 mechanism mean and how does selinexor work differently from other myeloma drugs?

XPO1 stands for Exportin 1, and understanding selinexor’s mechanism requires first understanding a basic cellular process most cancer drugs don’t touch at all: how proteins move between the nucleus and the rest of the cell.

The basic biology — nuclear transport

Every cell has a nucleus, where DNA lives and where many critical regulatory proteins need to do their work. But proteins are made outside the nucleus and need to be actively transported in and out through tiny pores in the nuclear membrane. This transport isn’t passive — it’s managed by specific “carrier” proteins, and exportin 1 (XPO1) is the primary carrier responsible for moving a large group of proteins out of the nucleus and into the rest of the cell.

This matters enormously for cancer because among the proteins XPO1 routinely exports are tumor suppressor proteins — proteins like p53, p21, and FOXO, whose entire job is to sit inside the nucleus and tell a cell to stop dividing, repair damage, or self-destruct (apoptosis) if something has gone wrong. If these tumor suppressors get pumped out of the nucleus and kept in the cytoplasm, they can’t do their job — the cell loses its internal “off switch.”

What cancer cells do with this

Many cancers, including multiple myeloma, exploit this system by overexpressing XPO1 — essentially running the export pump harder than normal. This keeps tumor suppressor proteins chronically exiled from the nucleus, effectively disabling the cell’s natural brakes on uncontrolled growth, while also affecting other regulatory pathways like NF-κB signaling, which myeloma cells depend on for survival.

How selinexor reverses this

Selinexor is a selective inhibitor of nuclear export that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation.

Breaking that down into what actually happens:

Selinexor physically blocks XPO1, preventing it from carrying its cargo of tumor-suppressor proteins out of the nucleus
Tumor suppressors accumulate inside the nucleus instead of being exiled to the cytoplasm — restoring their access to DNA and their ability to trigger growth arrest or programmed cell death
NF-κB signaling is inhibited — this is a pathway myeloma cells rely on heavily for survival signals, and selinexor disrupts it as a secondary effect
Translation of oncogenic mRNAs is reduced — meaning the genetic instructions for cancer-promoting proteins get less efficiently converted into actual protein

The net effect: myeloma cells, which have become dependent on chronic tumor-suppressor exile to survive and proliferate, suddenly have their “off switches” restored — triggering growth arrest or cell death specifically in cells that had become reliant on this evasion mechanism.

Why “first-in-class” is an accurate description, not marketing language

This is genuinely a different category of action compared to every other myeloma drug we’ve discussed in this conversation:

Lenalidomide/pomalidomide (immunomodulatory drugs) work by binding cereblon, altering which proteins get tagged for degradation, and boosting immune-mediated attack on myeloma cells
Bortezomib and other proteasome inhibitors block the cell’s protein disposal system, causing toxic protein buildup that myeloma cells (which produce enormous quantities of antibody protein) are especially vulnerable to
Daratumumab and other anti-CD38 antibodies work through the immune system, flagging myeloma cells for destruction by immune cells
Selinexor is the only one of these that works by controlling where existing proteins are located within the cell, rather than degrading them, blocking their synthesis, or flagging cells for immune attack

Why this also explains some of the distinctive side effects

Because XPO1 is involved in normal cellular regulation throughout the body — not just in cancer cells — inhibiting it broadly affects normal cells too, which helps explain selinexor’s side-effect pattern:

Thrombocytopenia relates to effects on platelet-producing cells in the bone marrow, where normal nuclear export processes are also disrupted
Fatigue and decreased appetite are thought to relate to effects on normal cellular metabolism and possibly central nervous system pathways affected by altered protein localization
Hyponatremia is a less fully understood effect, but is thought to relate to disruption of normal hormonal regulatory pathways that also depend on nuclear-cytoplasmic protein shuttling

This systemic, mechanism-linked side-effect pattern is different from, say, a kinase inhibitor’s “off-target” effects on unrelated kinases — selinexor’s side effects are a more direct consequence of disrupting a fundamental cellular transport process that healthy cells also rely on, just to a lesser degree than the cancer cells that have become dependent on dysregulated export.